Axonics Shares Fall Despite Australia's Approval for R20 SNM Device

Axonics, Inc. (AXNX) has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia.This cutting-edge device features a 20-year functional life and reduces recharge frequency to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15). Paired with intuitive remote control and enhanced MRI compatibility, the R20 builds on Axonics’ c ...